Summit Therapeutics Submits Ivonescimab BLA to FDA for EGFR‑Mutated NSCLC Post Third‑Gen TKI
Summit Therapeutics (NASDAQ: SMMT), the US partner of Akeso Inc. (HKG: 9926), announced the submission of...
Akeso Biopharma
Akeso’s Cadonilimab Wins FDA Nod for Global Phase 3 Gastric Cancer Study
Akeso Biopharma (HKG: 9926) announced that the U.S. FDA approved cadonilimab in combination with chemotherapy...
Akeso Secures NMPA Approval for AK152 – First Bispecific Antibody Targeting Alzheimer’s in China
Akeso Inc. (HKG: 9926) announced that its self‑developed bispecific antibody AK152 has received regulatory approval...
Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer
Akeso Inc. (HKG: 9926) announced that its proprietary bispecific antibody ivonescimab (AK112) has been granted...
Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC
Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...
Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC
Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...
Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
China-based Akeso Biopharma (HKG: 9926) announced that the first patient has been enrolled in the phase...
Akeso Enrolls First Patient in Phase III Trial of Ivonescimab for Pancreatic Cancer
China-based Akeso Biopharma (HKG: 9926) announced on July 24, 2025, that the first patient has...
AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics
UK-based AstraZeneca plc (AZ, NASDAQ: AZN) is reportedly in negotiations with Summit Therapeutics, the US...
Akeso Biopharma Initiates Phase Ia Clinical Study for Trop2/Nectin4 Bispecific ADC AK146D1
China-based Akeso Biopharma (HKG: 9926) announced the initiation of a Phase Ia clinical study for...
Akeso Biopharma Wins NMPA Approval for New Cadonilimab Indication
China-based Akeso Biopharma (HKG: 9926) announced that it has received another indication approval from the...
Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC
China-based Akeso, Inc. (HKG: 9926) announced that its supplementary New Drug Application (sNDA) for ivonescimab,...
Akeso’s Penpulimab Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
China-based Akeso, Inc. (HKG: 9926) announced that it has received marketing approval from the US...
Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
China-based Akeso, Inc. (HKG: 9926) announced strongly positive results from the regulatory Phase III AK112-306/HARMONi-6...
Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National...
Akeso Biopharma Partners with Virogin to Test Ivonescimab and VG201 in Colorectal Cancer Trial
China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...
Akeso Biopharma Reports 53% Revenue Decline in 2024 Despite Growth in Product Sales
China-based Akeso Biopharma (HKG: 9926) released its 2024 financial report, recording RMB 2.124 billion (USD...
TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies
Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...
Akeso Biopharma’s Penpulimab Approved for First-Line NPC Treatment
China-based Akeso Biopharma (HKG: 9926) announced receiving another indication approval from the National Medical Products...
Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...